Amorphous Calcium Prevents Bone Loss and Assists in Maintaining Strong Bone

Study objective:

Comparing the effects of amorphous calcium derived from either Gastrolith or synthetic amorphous calcium carbonate with those of crystalline calcium, found in most popular crystalline calcium carbonate (Caltrate, Pfizer) or citrate (GNC) supplements, in an osteoporosis model in animals.

Study description:

• Osteoporosis was induced by ovariectomy in 101 rats and followed by 3 months treatment  with one of the calcium supplements; synthetic amorphous calcium (ACC), natural amorphous calcium (Gastrolith), crystalline calcium carbonate (Pfizer) or calcium citrate (GNC)
• Researchers used an accurate and advanced micro-CT technology in order to measure bone loss, bone construction rate and bone strength.
• Blood and urine biochemical markers were examined by standard & well-established techniques.

Study results:

Amorphous calcium carbonate (ACC) demonstrated:

1. 50% reduction in bone loss vs. Caltrate (Pfizer) and Calcium-Citrate (GNC)
2. 34% increase in bone formation induction vs. Caltrate (Pfizer) and Calcium-Citrate (GNC).
3. 37% increase  in mechanical strength vs. Caltrate (Pfizer) and Calcium-Citrate (GNC).

The study was published in “Health” scientific journal, in a special edition dedicated to new break-through treatments for osteoporosis:

Galit Shaltiel, Elad Bar-David, Oren E. Meiron, Eitan Waltman, Assaf Shechter,

Eliahu D. Aflalo, David Stepensky, Amir Berman, Berdine R. Martin, Connie M. Weaver & Amir Sagi. Bone loss prevention in ovariectomized rats using stable amorphous calcium carbonate (2013) Vol.5, No.7A2, 18-29.